Robert Hsu

Dr. Robert Hsu is an Assistant Professor of Medicine in the Division of Medical Oncology at University of Southern California focusing on thoracic cancers. Dr. Hsu completed his medical school training at Tulane University School of Medicine followed by Internal Medicine residency training at University of Miami/Jackson Memorial and then hematology and oncology training at Los Angeles County+University of Southern California where he served as chief fellow for medical oncology.

His research interests are focused in lung cancer research along with cancer disparities across multiple solid tumor types. His research includes projects involving comprehensive genomic profiling looking at biomarkers in lung cancer, retrospective database work looking at lung cancer patients treated at USC looking at mutation differences among different ethnicities particularly Hispanics, epidemiological research looking at lung and thyroid cancer incorporating the California Cancer Registry, and translational research looking at tumor microenvironment and ethnicities in lung and breast cancer.

• International Association for the Study of Lung Cancer: Academy Award, 2024
• University of Southern California: Best Research Award at USC Medical Oncology Fellows Research Symposium, 2021-2022
• Summit on National and Global Cancer Health Disparities Travel Award, 2018
• Asian Pacific American Medical Student President’s Award for Distinguished Service, 2017
• Tulane University School of Medicine: Southern Section-American Federation for Clinical Research Travel Award, 2014
• AmeriCorps: AmeriCorps Segal Education Award, 2010-2011
• Cornell University: Cum Laude Distinction, 2009
• Cornell University: Cornell University Community Partnership Grant, 2008
• National Institutes of Health: NIH Summer Student Intramural Award, 2007

• Impact of Modern Systemic Therapies on Survival in Patients with Anaplastic Thyroid Cancer: A Single-Center Retrospective Cohort Review Drugs Real World Outcomes. 2025 May 16. . View in PubMed
• Deciding where Trop-2 directed antibody drug conjugates work in non-small cell lung cancer: the not so straightforward road Transl Cancer Res. 2025 Feb 28; 14(2):679-684. . View in PubMed
• Gender and Geographic Characteristics Among Thoracic, GI, and Breast Oncology Editorial Boards: Disparities and Measures to Address Gaps JCO Glob Oncol. 2025 Feb; 11:e2400656. . View in PubMed
• Real-World Incidence of Anaplastic Lymphoma Kinase Alterations in Hispanics with Non-Small Cell Lung Cancer at a Large Academic Institution in Los Angeles Cancer Res Commun. 2025 Feb 01; 5(2):277-286. . View in PubMed
• Advances in adoptive cell therapies in small cell lung cancer Explor Target Antitumor Ther. 2025; 6:1002302. . View in PubMed
• The current landscape and prospects of antibody-drug conjugates for lung cancer brain metastases: a narrative review Transl Lung Cancer Res. 2024 Dec 31; 13(12):3778-3794. . View in PubMed
• Assessing the predictive role of platelet-lymphocyte ratio in EGFR-mutated non-small cell lung cancer patients treated with tyrosine kinase inhibitors: an analysis across TKI generations Discov Oncol. 2024 Nov 21; 15(1):689. . View in PubMed
• Anti-MET Antibody Therapies in Non-Small-Cell Lung Cancer: Current Progress and Future Directions Antibodies (Basel). 2024 Oct 18; 13(4). . View in PubMed
• Evaluation of markers of immunity in different metastatic immune microenvironments suggests more suppression within breast to liver metastases in breast cancer Breast Cancer Res Treat. 2024 Jul; 206(2):245-259. . View in PubMed
• Cost effectiveness of immunotherapy combination therapies for endometrial cancer Gynecol Oncol Rep. 2024 Apr; 52:101351. . View in PubMed
• Characterization of Thyroid Cancer among Hispanics in California, USA, from 2010 to 2020 Cancers (Basel). 2024 Mar 08; 16(6). . View in PubMed
• Treatment approaches in advanced penile cancer: targeted therapies and immunotherapy Front Oncol. 2024; 14:1457006. . View in PubMed
• A narrative review of the efficacy and safety FDA-approved antibody-drug conjugates in older patients AME Medical Journal. 2024. . View in PubMed
• ALK inhibitors in cancer: mechanisms of resistance and therapeutic management strategies Cancer Drug Resist. 2024; 7:20. . View in PubMed
• A narrative review on perioperative systemic therapy in non-small cell lung cancer Explor Target Antitumor Ther. 2024; 5(4):931-954. . View in PubMed
• Addressing the unmet need in NSCLC progression with advances in second-line therapeutics Explor Target Antitumor Ther. 2024; 5(6):1297-1320. . View in PubMed
• Complete response with pembrolizumab in recurrent squamous cell carcinoma of the oral tongue: A case report Oral Oncol. 2023 Dec; 147:106597. . View in PubMed
• The Development and Role of Capmatinib in the Treatment of MET-Dysregulated Non-Small Cell Lung Cancer-A Narrative Review Cancers (Basel). 2023 Jul 10; 15(14). . View in PubMed
• A Multicenter Retrospective Chart Review of Clinical Outcomes Among Patients With KRAS G12C Mutant Non-Small Cell Lung Cancer Clin Lung Cancer. 2023 05; 24(3):228-234. . View in PubMed
• A narrative review of antibody-drug conjugates in EGFR-mutated non-small cell lung cancer Front Oncol. 2023; 13:1252652. . View in PubMed
• Impact of gender and mutational differences in hormone receptor expressing non-small cell lung cancer Front Oncol. 2023; 13:1215524. . View in PubMed
• Real world prognostic utility of platelet lymphocyte ratio and nutritional status in first-line immunotherapy response in stage IV non-small cell lung cancer Cancer Treat Res Commun. 2023; 36:100752. . View in PubMed
• Treatment approaches for FGFR-altered urothelial carcinoma: targeted therapies and immunotherapy Front Immunol. 2023; 14:1258388. . View in PubMed
• Evaluating Real World Mutational Differences Between Hispanics and Asians in NSCLC at a Large Academic Institution in Los Angeles Clin Lung Cancer. 2022 11; 23(7):e443-e452. . View in PubMed
• Systemic Chemotherapies Retain Antitumor Activity in Desmoid Tumors Independent of Specific Mutations in CTNNB1 or APC: A Multi-institutional Retrospective Study Clin Cancer Res. 2022 09 15; 28(18):4092-4104. . View in PubMed
• Thyroid cancer incidence disparities among ethnic Asian American populations, 1990-2014 Ann Epidemiol. 2022 02; 66:28-36. . View in PubMed
• Characterization of mortality and high-risk characteristics of thyroid cancer in Filipinos using the California Cancer Registry Front Public Health. 2022; 10:1104607. . View in PubMed
• Molecular characterization of Kita-Kyushu lung cancer antigen (KK-LC-1) expressing carcinomas Oncotarget. 2021 Dec 07; 12(25):2449-2458. . View in PubMed
• The Genomics of Young Lung Cancer: Comprehensive Tissue Genomic Analysis in Patients Under 40 With Lung Cancer JTO Clin Res Rep. 2021 Jul; 2(7):100194. . View in PubMed
• The effects of high impact exercise intervention on bone mineral density, physical fitness, and quality of life in postmenopausal women with osteopenia: A retrospective cohort study Medicine (Baltimore). 2019 Mar; 98(11):e14898. . View in PubMed
• Methodological evaluation of the noninvasive estimation of central systolic blood pressure in nontreated patients: the Bogalusa Heart Study Blood Press Monit. 2017 Apr; 22(2):95-100. . View in PubMed
• Novel Pathophysiological Mechanisms in Hypertension Adv Exp Med Biol. 2017; 956:21-35. . View in PubMed
• Chagas Cardiomyopathy in New Orleans and the Southeastern United States Ochsner J. 2016; 16(3):304-8. . View in PubMed
• Abstracts of the 56th Annual Scientific Meeting of the Society for Gynecologic InvestigationMarch 17-21, 2009. Reprod Sci. 2009 Mar; 16(3 Suppl):69A-374A. . View in PubMed

• Angell, Trevor
• Jeong, Shinwu
• Lenz, Heinz-Josef
• Kim, Anthony
• Daneshmand, Siamak
• Djaladat, Hooman
• Gill, Inderbir
• Quinn, David